Quantcast

Latest bladder cancer Stories

2014-08-28 12:30:33

No overall statistically significant increased risk of bladder cancer in patients ever exposed to pioglitazone in a completed 10-year epidemiological study OSAKA, Japan, Aug. 28, 2014 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities including the United States (U.S.) Food and Drug Administration (FDA), the European Medicines Agency...

2014-08-11 08:28:56

SAN DIEGO, Aug. 11, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced that the U.S. FDA has granted Orphan Drug Designation to mocetinostat, a spectrum selective HDAC inhibitor, for diffuse large B-cell lymphoma (DLBCL). In June, mocetinostat was granted Orphan Drug Designation as a treatment for myelodysplastic syndrome (MDS). Orphan drug designation is also being sought for bladder cancer patients with specific genetic alterations. Mocetinostat is being...

2014-08-11 04:22:07

MT Services LLC informs plaintiffs on ongoing cases with Takeda Pharmaceutical, manufacturer of Actos (Pioglitazone hydrochloride) diabetes drug, seeking post-trial motions to lower $9Bil. verdict. NEW ORLEANS, Aug. 11 2014 /PRNewswire/ -- MT Services LLC, The Lawsuit Settlement News Reporting Company, reported today that there are still claims being filed, lawsuits being heard, and possible settlements discussions in the works, for patients of the reputed bad pharmaceutical drug...

cancer classification system
2014-08-10 05:02:57

Rayshell Clapper for redOrbit.com - Your Universe Online Researchers released some pretty incredible findings last week about cancer. In a multiple institute study including researchers and authors from the University of California at Santa Cruz (UCSC), the Buck Institute for Research on Aging, the University of California at San Francisco (UCSF), the University of North Carolina, Chapel Hill (UNC), and the Broad Institute of Harvard and MIT looked closely at how cancers are classified....

2014-08-04 23:05:10

Takeda Pharmaceuticals Co. and Eli Lilly & Co. moving for new trial Port Washington, New York (PRWEB) August 04, 2014 Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs and medical devices, reports that the plaintiffs who recently won a $9 billion punitive damages award in the first federal bellwether trial involving Takeda Pharmaceutical’s diabetes medication, Actos, say the verdict should be upheld. According to the...

2014-07-21 23:09:32

The Actos Lawsuit Filed on Behalf of a NY Man Who Developed Baldder Cancer Alleges Takedea Pharmaceuticals America Inc., Knew Their Diabetic Medication Caused Bladder Cancer But Did Not Inform Doctors and Patients Columbus, OH (PRWEB) July 21, 2014 The defective drug attorneys at Wright & Schulte LLC have filed an Actos lawsuit on behalf of a Schenectady, New York man who alleges that he developed bladder cancer as a result of taking Actos for more than a year to treat his Type II...

2014-07-18 08:24:51

BELLEVILLE, ON, July 18, 2014 /PRNewswire/ - Bioniche Life Sciences Inc. (TSX: BNC) today provided a key regulatory update on its flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) sterile suspension for the treatment of patients with Bacillus Calmette-Guérin (BCG) refractory high grade non-muscle invasive bladder cancer. MCNA U.S. Regulatory Update Following several months of active dialogue with the U.S. Food and Drug Administration (FDA),...

2014-07-06 23:01:27

The Firm is evaluating Actos lawsuits on behalf of long-term users of the Type 2 diabetes medication who allegedly developed bladder cancer due to Actos. (PRWEB) July 06, 2014 The federal court overseeing thousands of Actos lawsuits (http://www.theactoslawsuitcenter.com/) that allege long-term use of the Type-2 diabetes drug caused patients to develop bladder cancer held a Status Conference on June 19, 2014, Bernstein Liebhard LLP reports. According court documents filed in the U.S....

2014-07-01 16:30:36

Micromedic to continue developing its CellDetect® technology for monitoring the recurrence of bladder cancer TEL AVIV, Israel, July 1, 2014 /PRNewswire/ -- BioLight Life Sciences Investments Ltd. (OTC: BLGTY)(TASE: BOLT), a firm that invests in, manages and commercializes biomedical innovations grouped into clusters around defined medical conditions, announced today that Micromedic Technologies (TASE: MCTC), BioLight's cancer diagnostic cluster company, achieved successful...

2014-06-24 14:07:18

Centro Nacional de Investigaciones Oncologicas (CNIO) New mutations in cohesin proteins, which are closely associated with cell division, are very common in various types of cancers such as bladder cancer and melanoma Massive sequencing of cancer genomes brings to light new genes every day that could be involved in the process of tumour formation. A good example of this is cohesin, a ring-shaped protein complex that embraces DNA to control cell division. Just a few months ago, and...


Word of the Day
abrosia
  • Wasting away as a result of abstinence from food.
The word 'abrosia' comes from a Greek roots meaning 'not' and 'eating'.